ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Painting Peptides With Antimicrobial Potency Through Deep Reinforcement Learning.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The Applications of Machine Learning in Micro-Nano Materials Research: From High-Throughput Screening to Intelligent Design.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- DeepPANB: integrating protein language model with PaiNN equivariant graph neural networks for prediction of protein-nucleic acid binding sites.Briefings in bioinformatics · 2026Article
- PepMCP: a graph-based membrane contact probability predictor for membrane-lytic antimicrobial peptides.Bioinformatics (Oxford, England) · 2026Article
- Molecular Diversity, Structure-Function Relationship, Mechanism of Action, and Transformative Potential of Black Soldier Fly Antimicrobial Peptides Against Multidrug-Resistant Pathogens.Current issues in molecular biology · 2026Review
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- Painting Peptides With Antimicrobial Potency Through Deep Reinforcement Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Role of artificial intelligence in bacterial diagnostics and surveillance of anti-microbial resistance.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the post-antibiotic era, antimicrobial peptides (AMPs) are considered ideal drug candidates because of their lower likelihood of inducing resistance. Computational models provide an efficient way to design novel AMPs. However, current optimization and generation approaches are tailored for specific application scenarios, which hinders the ease of use. To address this challenge, a novel AMP design model named AMPainter is proposed. Based on deep reinforcement learning, AMPainter integrates optimization and generation tasks in a unified framework. AMPainter is applied to three types of peptides, including known AMPs, signal peptides (SPs), and random sequences. AMPainter outperforms ten related models in enhancing the activity of known AMPs on the predicted antimicrobial potency and diversity. Several AMPs demonstrate a 128-fold decrease in their actual minimal inhibitory concentrations (MICs). AMPainter evolves effective AMPs from membrane-active SPs with an experimental success rate of 80%. In terms of generation, de novo designed AMP from an inactive random sequence achieves an average MIC of 2.88 µM against four bacteria. In vitro MICs of peptides along the virtual evolutionary path match the predicted scores. Therefore, AMPainter can significantly improve the antimicrobial potency of various peptides, expand the AMP sequence space, and discover novel antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.